• Internist (GMC-registered)
• Cardiologist (GMC-registered)
• Zusatzbezeichung Intensivmedizin (“intensive care”, Ärztekammer Westfalen-Lippe)

Paulus graduated from Münster Medical School, Münster, Germany in 1997 after studying Medicine at the Universities of Heidelberg, Germany; Münster, Germany; Lille, France; and Georgetown University, Washington, USA. He received postgraduate training in Internal Medicine (Specialist Registration 2004), Cardiology (Specialist Registration 2006), and Intensive Care Medicine (“Zusatzbezeichnung Intensivmedizin”, 2011) in the Department of Cardiology and Angiology at the University of Münster. He worked there as a senior interventional cardiologist including postgraduate training in interventional cardiology until joining University of Birmingham in 2011. He still continues an appointment as researcher at University of Münster.

Paulus was a stipendiate of Cusanuswerk, Germany, and has received several prizes, including the prize for the best medical thesis from Heart Center Münster in 1998, the Woldemar-Mobitz Prize (2004) and the Bruno-Kisch Prize (2006) from the German Cardiac Society, and the Sibylle Hahne Prize for Medicine and Sciences from the University of Münster (2005).

Paulus is an active member of several research consortia and professional organisations. Among others, he sits on the steering committee of the German Atrial Fibrillation competence NETwork (AFNET), chairs the scientific documents committee of the European Heart Rhythm Association, and has contributed to the 2010 guidelines of the European Society of Cardiology on the management of atrial fibrillation. He is an Editorial Board Member of BMC Medicine, Heart Rhythm, and Europace, and serves as Editorial Consultant to The Lancet.

Paulus has trained cardiologists in interventional cardiology at University of Münster, and looks forward to joining the active team of interventional cardiologists at City and Sandwell Hospitals.

Paulus has published original research in recognised journals including the Lancet, Circulation, the Journal of Experimental Medicine, Nature Methods, and the Journal of Clinical Investigation. He started his research career during a research year at Georgetown University, Washington DC, USA. At University of Münster, his translational cardiovascular research group studies molecular mechanisms of heart disease. In parallel, he has initiated investigator-initiated controlled clinical trials to translate pathophysiological insights into new therapies for heart disease. In Birmingham, he expects to continue the evaluation and improvement of clinical management of patients with heart disease, especially cardiomyopathies, heart failure, and arrhythmias. In parallel, he will continue to apply transgenic technology to characterize novel  mechanisms of myocardial dysfunction and probe new “translational” therapies for heart disaese.

His research is currently supported by several independent funding agencies, including Fondation Leducq within the European North-Atlantic Atrial Fibrillation Research Alliance (ENAFRA), the German Research Foundation (DFG) within the Collaborative Research Center “Molecular Cardiovascular Imaging” in Münster, and the European Union (FP7) through the European Network for Translational Research in Atrial Fibrillation (EUTRAF). He is currently building up a research group at University of Birmingham, so look out for job opportunities if you have an interest in the field!

Links:

• ENAFRA http://141.76.248.33:8080/enafra/portal/
• EUTRAF www.eutraf.eu
• Collaborative Research Centre Molecular Cardiovascular Imaging www.sfbmobil.de
• European Heart Rhythm Association http://www.escardio.org/communities/EHRA/Pages/welcome.aspx
• Atrial Fibrillation competence NETwork (AFNET) www.kompetenznetz-vorhofflimmern.de
• The EAST trial www.easttrial.org
• University of Birmingham Research Group: www.birmingham.ac.uk/heart-failure-arrhythmias

Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U, U. R, Samol A, Steinbeck G, Treszl A, Wegscheider K, Breithardt G. Comparing short-term and long-term antiarrhythmic drug therapy after cardioversion of atrial fibrillation - a prospective, randomised, open, blinded outcome assessment trial. Lancet. 2012; 380: 238-46.

Fabritz CL, Fortmueller L, Yu TY, Paul M, Kirchhof P. Can preload-reducing therapy prevent disease progression in arrhythmogenic right ventricular cardiomyopathy? Experimental evidence and concept for a clinical trial. Prog Biophys Mol Biol. 2012; published on line 27 Aug 2012.

Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Vardas P, Al-Attar N, Alfieri O, Angelini A, Blomstrom-Lundqvist C, Colonna P, De Sutter J, Ernst S, Goette A, Gorenek B, Hatala R, Heidbuchel H, Heldal M, Kristensen SD, Le Heuzey JY, Mavrakis H, Mont L, Filardi PP, Ponikowski P, Prendergast B, Rutten FH, Schotten U, Van Gelder IC, Verheugt FW. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Eur HJ, published on line 25 August 2012

Camm AJ, al Kathib SM, Calkins H, Halperin J, Kirchhof P, Lip GYH, Nattel S, Ruskin J, Banerjee A, Blendea D, Guasch E, Needleman M, Savelieva I, Viles-Gonzalez JF, Williams E. A proposal for new clinical concepts in the management of atrial fibrillation. Am J Cardiol. 2012; in press.

Rizos T, Guntner J, Jenetzky E, Marquardt L, Reichardt C, Becker R, Reinhardt R, Hepp T, Kirchhof P, Aleynichenko E, Ringleb P, Hacke W, Veltkamp R. Continuous Stroke Unit Electrocardiographic Monitoring Versus 24-Hour Holter Electrocardiography for Detection of Paroxysmal Atrial Fibrillation After Stroke. Stroke. 2012; published on line 7 Aug 2012

Hofmann F, Fabritz L, Stieber J, Schmitt J, Kirchhof P, Ludwig A, Herrmann S. Ventricular HCN channels decrease the repolarization reserve in the hypertrophic heart. Cardiovasc Res. 2012; 95: 317-26.

McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012; 33: 1787-847.

Landeta F, Hoffmeier A, Fuchs M, Scheld H, Maintz D, Stypmann J, Schober O, Kirchhof P, Spieker T, Waltenberger J. Ectopic thyroid mass in the heart. Lancet. 2012; 379: 1762.

Click on this link for a full list of publications. 

More information about Paulus Kirchhof is found at http://circ.ahajournals.org/content/123/24/f139.full.pdf